|
π¦
|
The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis.
S. Welsh,
W. Bellamy,
M. Briehl,
G. Powis
|
8 |
2002 |
8
π¦
|
|
π¦
|
Hypoxia inducible factor as a cancer drug target.
S. Welsh,
G. Powis
|
8 |
2003 |
8
π¦
|
|
π
|
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
15 auth.
E. Jonasch,
F. Donskov,
O. Iliopoulos,
W. Rathmell,
V. Narayan,
B. Maughan,
S. Oudard,
T. Else,
J. Maranchie,
S. Welsh,
...
S. Thamake,
E. Park,
R. Perini,
W. Linehan,
R. Srinivasan
|
8 |
2021 |
8
π
|
|
π¦
|
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
S. Welsh,
P. Corrie
|
8 |
2015 |
8
π¦
|
|
π¦
|
Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1Ξ±
S. Welsh,
Ryan R. Williams,
L. Kirkpatrick,
G. Paine-Murrieta,
G. Powis
|
8 |
2004 |
8
π¦
|
|
π¦
|
The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation.
S. Welsh,
Ryan R. Williams,
Anne Birmingham,
D. Newman,
D. Kirkpatrick,
G. Powis
|
8 |
2003 |
8
π¦
|
|
π
|
Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1Ξ±
7 auth.
M. Koh,
T. Spivak-Kroizman,
S. Venturini,
S. Welsh,
Ryan R. Williams,
D. Kirkpatrick,
...
G. Powis
|
8 |
2008 |
8
π
|
|
π¬
|
Hypoxia-Inducible Factor-1Ξ± and the Glycolytic Phenotype in Tumors
I. Robey,
Anthony D. Lien,
S. Welsh,
B. Baggett,
R. Gillies
|
7 |
2005 |
7
π¬
|
|
π¦
|
Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
S. Welsh,
H. Rizos,
R. Scolyer,
G. Long
|
7 |
2016 |
7
π¦
|
|
π¬
|
Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors.
I. Robey,
Anthony D. Lien,
S. Welsh,
B. Baggett,
R. Gillies
|
6 |
2005 |
6
π¬
|
|
π
|
Delayed immune-related adverse events with anti-PD1-based immunotherapy in melanoma.
36 auth.
C. Owen,
X. Bai,
T. Quah,
S. Lo,
C. Allayous,
S. Callaghan,
C. Martinez-Vila,
R. Wallace,
P. Bhave,
I. Reijers,
N. Thompson,
V. Vanella,
C. Gerard,
S. Aspeslagh,
A. Labianca,
...
A. Khattak,
M. MandalΓ ,
W. Xu,
B. Neyns,
O. Michielin,
C. Blank,
S. Welsh,
A. Haydon,
S. Sandhu,
J. Mangana,
J. McQuade,
P. Ascierto,
L. Zimmer,
D.B. Johnson,
A. Arance,
P. Lorigan,
C. LebbΓ©,
M. Carlino,
R. Sullivan,
G. Long,
A. Menzies
|
6 |
2021 |
6
π
|
